Discontinuation of proton pump inhibitors in patients on long‐term therapy: a double‐blind, placebo‐controlled trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Background: The proportion of proton pump inhibitor users on long‐term therapy who can discontinue proton pump inhibitor (PPI) medication without developing symptoms is unknown. Aim: To determine the proportion of patients on long‐term PPI therapy who are able to discontinue PPIs without developing symptoms. Methods: Patients on long‐term PPIs, without a history of peptic ulcer or esophagitis underwent upper endoscopy. Patients were randomized double‐blindly to taper down or continue a constant dosage of omeprazole for three weeks. Thereafter, all patients discontinued PPIs. Results: Of the 97 patients enrolled, had used PPIs for 48 months, 78% had GERD. A total of 27% did not use PPIs during the year after discontinuation, 31% of the patients randomized to tapering discontinued PPIs and 22% of those who did not could discontinue therapy (NS). Gastro‐oesophageal reflux disease (GERD) patients were more prone to continue PPIs than non‐GERD patients. Only 16 (21%) of GERD patients were off PPIs vs. 48% of patients without GERD (p < 0.05). Serum gastrin was higher at baseline in GERD patients who resumed PPIs versus non‐resumers (p < 0.05). GERD and serum gastrin were independent predictors of PPI requirement. Conclusions: Discontinuation of PPI was successful in 27% of long‐term PPI users. GERD patients had more difficulty discontinuing PPIs than non‐GERD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum, H. L., Arnestad, J. S., Brenna, E., Eide, I., Syversen, U., & Sandvik, A. K. (1996) · Gut · doi:10.1136/gut.39.5.649 · Cited by 243
Cited by
Rosen, R., Vandenplas, Y., Singendonk, M., Cabana, M., DiLorenzo, C., Gottrand, F., Gupta, S., Langendam, M., Staiano, A., Thapar, N., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001889 · Cited by 1,557
Vandenplas, Y., Rudolph, C. D., Committee Members:, Di Lorenzo, C., Hassall, E., Liptak, G., Mazur, L., Sondheimer, J., Staiano, A., Thomson, M., et al. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181b7f563 · Cited by 742
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.7193 · Cited by 729
Overprescribing proton pump inhibitors
Forgacs, I., & Loganayagam, A. (2008) · BMJ · doi:10.1136/bmj.39406.449456.be · Cited by 553
Use of proton pump inhibitors and risk of osteoporosis-related fractures
Targownik, L. E., Lix, L. M., Metge, C. J., Prior, H. J., Leung, S., & Leslie, W. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071330 · Cited by 436
Kahrilas, P. J., Shaheen, N. J., & Vaezi, M. F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.044 · Cited by 431
Reimer, C., Søndergaard, B., Hilsted, L., & Bytzer, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.058 · Cited by 356
AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review
Targownik, L. E., Fisher, D. A., & Saini, S. D. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.247 · Cited by 320
The Enterochromaffin-like [ECL] Cell—Central in Gastric Physiology and Pathology
Waldum, H. L., Sørdal, Ø. F., & Mjønes, P. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102444 · Cited by 45
Metadata
- Authors
- BJÖRNSSON, E., ABRAHAMSSON, H., SIMRÉN, M., MATTSSON, N., JENSEN, C., AGERFORZ, P., & KILANDER, A.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-08-31
- Volume
- 24
- Issue
- 6
- Pages
- 945-954
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2086185330
- Cited by
- 186
- References
- 1
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.